latest update:
[TrialBase DB]

trial summary · NCT07725406

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

A Phase Ib, Dose-Escalation Study of Augmented Lymphodepletion and CAR T-cell Priming With Low-dose Total Body Irradiation in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphomas and Multiple Myeloma Receiving Treatment With Commercial CD19 or BCMA-directed CAR T-cell Therapies

Trial record from the TrialBase DB dataset, status RECRUITING, condition Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Weill Medical College of Cornell University. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07725406phase PHASE1enrollment 32start 2026-11

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This is a clinical trial to evaluate the safety of combining CAR T-cell therapy with low-dose total body irradiation (LD-TBI) in patients with previously treated large B-cell lymphoma (LBCL) or multiple myeloma (MM). The investigators' hypothesis is that the combination will make the immune system more active in fighting cancer by increasing the display of antigens and activating pathways that lead to cell death, including death receptors like FAS and TRAIL2. This approach is expected to help the CAR T cells grow and last longer, leading to stronger anti-tumor effects and more cancer cell deaths. Participants will receive LDTBI treatment before their CAR T cell therapy and will be followed up for 2 years.

Source record: https://clinicaltrials.gov/study/NCT07725406

Facts

registry idNCT07725406
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionRelapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
sponsorWeill Medical College of Cornell University
sponsor classOTHER
enrollment32
start date2026-11
primary completion2028-08-01
completion2033-08-31
results postednot reported

Conditions

  • Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
  • Relapsed or Refractory Multiple Myeloma (MM)

Interventions

  • Lymphodepleting chemotherapy: Cyclophosphamide
  • Lymphodepleting chemotherapy: Bendamustine
  • Lymphodepleting chemotherapy: Fludarabine
  • Lisocabtagene Maraleucel
  • Axicabtagene Ciloleucel
  • Ciltacabtagene Autoleucel
  • Low-Dose Total Body Irradiation

Countries

  • United States

Intervention types: DRUG, OTHER, RADIATION

Work with this record